RecruitingNCT06749015

A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

A Multicenter, Retrospective, Observational Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

Sponsor

Fudan University

Enrollment

100 participants

Start Date

Mar 1, 2021

Study Type

OBSERVATIONAL

Conditions

Metastatic Colorectal Cancer BRAF V600 Mutation

Summary

Previous studies have shown that BRAFV600E mutant mCRC patients have a shorter survival time than BRAF wild type mCRC patients. For Chinese patients, however, it remains unclear about the BRAF gene mutation rate, diagnosis, prognosis and survival data in people with BRAFV600E mutant mCRC . This real-world, multicenter non-interventional study (NIS) will describe the mutation rate, treatment patterns, effectiveness and safety of current treatment regimens in BRAFV600E mutant mCRC patients in China.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a targeted treatment approach for people with metastatic colorectal cancer (bowel cancer that has spread) that has a specific genetic mutation called BRAFV600E. This mutation makes the cancer behave more aggressively, and the study is looking at drugs that specifically target this mutation. **You may be eligible if...** - You have been diagnosed with colorectal cancer (colon or rectal cancer) that has spread and cannot be surgically removed - Your tumor has been confirmed to carry the BRAFV600E mutation through laboratory testing **You may NOT be eligible if...** - You have a history of chronic inflammatory bowel disease, chronic diarrhea, or recurrent bowel obstruction - You have active severe infections - You have brain metastases causing symptoms Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.